Previous 10 | Next 10 |
Angion Biomedica Corp was the fifth worst IPO of 2021, down over 80% as its lead candidate failed one Phase 3 and two Phase 2 trials. The company recently announced a pivot to its other clinical asset – a potential therapy for fibrotic diseases of the kidney and lungs. Trad...
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a...
Gainers: American Virtual Cloud Technologies (NASDAQ:AVCT) +50%. Petros Pharmaceuticals (NASDAQ:PTPI) +28%. BioLineRx (NASDAQ:BLRX) +24%. SigmaTron (NASDAQ:SGMA) +20%. Oracle (NYSE:ORCL) +15%. Sprinklr (NYSE:CXM) +15%. Nam Tai Property (NYSE:NTP) +14%. Vasta (NASDAQ:VSTA) +15%. Bottomline Tec...
Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +37%, Biofrontera BFRI +20%, ABVC BioPharma (NASDAQ:ABVC) +12%, Halozyme Therapeutics (NASDAQ:HALO) +11%, Context Therapeutics CNTX +9%. Losers: Angion Biomedica (NASDAQ:ANGN) -22%, Ensysce Biosciences ...
Everbridge (NASDAQ:EVBG) -36% on CEO resignation, downgrade Code Chain New Continent (NASDAQ:CCNC) -33% on proposed common stock and warrants offering. Angion Biomedica (NASDAQ:ANGN) -21% after mid-stage acute kidney injury drug misses primary endpoint American O...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced re...
Shares of Angion Biomedica (NASDAQ:ANGN) have tumbled 17% after it reported that a phase 2 trial of its cardiac-surgery associated acute kidney injury drug ANG-3777 missed its primary endpoint. That endpoint was percentage increase in serum creatinine based upon the area under the c...
-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3...
Angion Biomedica (NASDAQ:ANGN): Q3 GAAP EPS of -$0.53 beats by $0.19. Revenue of $1.46M (+75.9% Y/Y) beats by $0.4M. Press Release For further details see: Angion Biomedica EPS beats by $0.19, beats on revenue
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provi...
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...